Skip to main content
Erschienen in: Neurological Sciences 7/2022

12.02.2022 | Original Article

Cognitive impairment and markers of optical neurodegeneration in early multiple sclerosis

verfasst von: Renata Silva, Pedro Coelho, Mafalda Seabra, Inês Laranjinha, Daniela Vieira, Octávia Costa, Jennifer Jesus, Ana Cláudia Fonseca, Sónia Costa, Inês Ferreira, João Lemos, Cláudia Sousa, José Vale, Maria José Sá, Luís Ruano

Erschienen in: Neurological Sciences | Ausgabe 7/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cognitive impairment and retinal atrophy have been proposed as two potential markers of neurodegeneration in multiple sclerosis (MS). We aimed at assessing the relation between peripapillary retinal nerve fiber layer (pRNFL) and macular ganglion cell layer (mGCL) atrophy and cognitive performance in early MS.

Methods

This is a multicenter cross-sectional study on patients with early MS (clinically isolated syndrome and relapsing–remitting MS), with an EDSS score ≤ 3.0. Patients with previous optic neuritis, other ocular diseases, psychiatric illness, or recent relapse were excluded. All patients underwent standardized optical coherence tomography (OCT) and neuropsychological evaluation with validated tests for MS patients. Cognitive impairment was defined as having two cognitive tasks below age- and education-adjusted norms.

Results

We recruited 52 patients with early MS, with an average age of 37 years (SD = 10.5), an average disease duration of 3.69 years (SD = 2.3), and a median EDSS of 1.0 (IQR = 0.5). In this sample, 15/52 patients presented cognitive impairment. Regarding OCT measurements, 7/52 patients had an average pRNFL below the 5th percentile and 2/52 had an average mGCL below the 5th percentile. The average pRNFL thickness was comparable in cognitively impaired and cognitively preserved patients (100.3 μm vs 103.1 μm, p = 0.52); the average mGCL thickness had also similar values between groups (50.5 μm vs 53 μm, p = 0.38).

Conclusions

Cognitive impairment was frequent in our sample of early MS. However, no association with reduced pRNFL or mGCL thickness was found. When compared to OCT, cognitive assessment could provide an earlier marker of neurodegeneration in MS.
Literatur
1.
Zurück zum Zitat Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7(12):1139–1151CrossRef Chiaravalloti ND, DeLuca J (2008) Cognitive impairment in multiple sclerosis. Lancet Neurol 7(12):1139–1151CrossRef
2.
Zurück zum Zitat Ruano L et al (2017) Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler 23(9):1258–1267CrossRef Ruano L et al (2017) Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler 23(9):1258–1267CrossRef
3.
Zurück zum Zitat Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, Sormani MP, Smith T, Häring DA, Piani Meier D, Tomic D (2016) Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 22(10):1297–305CrossRef Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, Sormani MP, Smith T, Häring DA, Piani Meier D, Tomic D (2016) Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler 22(10):1297–305CrossRef
4.
Zurück zum Zitat Alonso R, Gonzalez-Moron D, Garcea O (2018) Optical coherence tomography as a biomarker of neurodegeneration in multiple sclerosis: A review. Mult Scler Relat Disord 22:77–82CrossRef Alonso R, Gonzalez-Moron D, Garcea O (2018) Optical coherence tomography as a biomarker of neurodegeneration in multiple sclerosis: A review. Mult Scler Relat Disord 22:77–82CrossRef
5.
Zurück zum Zitat Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA (2018) Multiple sclerosis Nat Rev Dis Primers 4(1):43CrossRef Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA (2018) Multiple sclerosis Nat Rev Dis Primers 4(1):43CrossRef
6.
Zurück zum Zitat Bsteh G, Berek K, Hegen H, Altmann P, Wurth S, Auer M, Zinganell A, Di Pauli F, Rommer P, Leutmezer F, Deisenhammer F, Berger T (2020) Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. Mult Scler, https://doi.org/10.1177/1352458520935724 Bsteh G, Berek K, Hegen H, Altmann P, Wurth S, Auer M, Zinganell A, Di Pauli F, Rommer P, Leutmezer F, Deisenhammer F, Berger T (2020) Macular ganglion cell-inner plexiform layer thinning as a biomarker of disability progression in relapsing multiple sclerosis. Mult Scler, https://​doi.​org/​10.​1177/​1352458520935724​
7.
Zurück zum Zitat Hegen H, Bsteh G, Berger T (2018) ‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis? Eur J Neurol 25(9):1107-e101CrossRef Hegen H, Bsteh G, Berger T (2018) ‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis? Eur J Neurol 25(9):1107-e101CrossRef
8.
Zurück zum Zitat Damasceno A, Damasceno BP, Cendes F (2016) No evidence of disease activity in multiple sclerosis: implications on cognition and brain atrophy. Mult Scler 22(1):64–72CrossRef Damasceno A, Damasceno BP, Cendes F (2016) No evidence of disease activity in multiple sclerosis: implications on cognition and brain atrophy. Mult Scler 22(1):64–72CrossRef
9.
Zurück zum Zitat Van Schependom J, Guldolf K, D’hooghe MB et al (2019) Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in. Transl Neurodegener 8:37CrossRef Van Schependom J, Guldolf K, D’hooghe MB et al (2019) Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in. Transl Neurodegener 8:37CrossRef
10.
Zurück zum Zitat Coric D et al (2018) Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers. Mult Scler 24(2):158–166CrossRef Coric D et al (2018) Cognitive impairment in patients with multiple sclerosis is associated with atrophy of the inner retinal layers. Mult Scler 24(2):158–166CrossRef
11.
Zurück zum Zitat Toledo J et al (2008) Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler 14(7):906–912CrossRef Toledo J et al (2008) Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler 14(7):906–912CrossRef
12.
Zurück zum Zitat Ashtari F, Emami P, Akbari M (2015) Association between retinal nerve fiber layer thickness and magnetic resonance imaging findings and intelligence in patients with multiple sclerosis. Adv Biomed Res 4:223CrossRef Ashtari F, Emami P, Akbari M (2015) Association between retinal nerve fiber layer thickness and magnetic resonance imaging findings and intelligence in patients with multiple sclerosis. Adv Biomed Res 4:223CrossRef
13.
Zurück zum Zitat Frau J et al (2018) A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. BMC Neurol 18(1):67–67CrossRef Frau J et al (2018) A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. BMC Neurol 18(1):67–67CrossRef
14.
Zurück zum Zitat Anhoque CF et al (2013) Cognitive impairment and optic nerve axonal loss in patients with clinically isolated syndrome. Clin Neurol Neurosurg 115(7):1032–1035CrossRef Anhoque CF et al (2013) Cognitive impairment and optic nerve axonal loss in patients with clinically isolated syndrome. Clin Neurol Neurosurg 115(7):1032–1035CrossRef
15.
Zurück zum Zitat Thompson AJ et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173CrossRef Thompson AJ et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173CrossRef
16.
Zurück zum Zitat Lublin FD et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286CrossRef Lublin FD et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286CrossRef
17.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRef Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRef
18.
Zurück zum Zitat Bever CT Jr et al (1995) The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study. Mult Scler 1(3):165–169CrossRef Bever CT Jr et al (1995) The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study. Mult Scler 1(3):165–169CrossRef
19.
Zurück zum Zitat Neves M et al (2017) Verbal selective reminding test (six trial administration) Portuguese normative data. Appl Neuropsychol Adult 30:1–9 Neves M et al (2017) Verbal selective reminding test (six trial administration) Portuguese normative data. Appl Neuropsychol Adult 30:1–9
20.
Zurück zum Zitat Krupp LB et al (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–3CrossRef Krupp LB et al (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46(10):1121–3CrossRef
21.
Zurück zum Zitat Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370CrossRef Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370CrossRef
22.
Zurück zum Zitat Oset M, Stasiolek M, Matysiak M (2020) Cognitive dysfunction in the early stages of multiple sclerosis-how much and how important? Curr Neurol Neurosci Rep 20(7):22CrossRef Oset M, Stasiolek M, Matysiak M (2020) Cognitive dysfunction in the early stages of multiple sclerosis-how much and how important? Curr Neurol Neurosci Rep 20(7):22CrossRef
23.
Zurück zum Zitat Schulz D et al (2006) Cognition in the early stage of multiple sclerosis. J Neurol 253(8):1002–1010CrossRef Schulz D et al (2006) Cognition in the early stage of multiple sclerosis. J Neurol 253(8):1002–1010CrossRef
24.
Zurück zum Zitat Achiron A, Barak Y (2003) Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 74(4):443–6CrossRef Achiron A, Barak Y (2003) Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 74(4):443–6CrossRef
25.
Zurück zum Zitat McNicholas N et al (2018) Cognitive dysfunction in early multiple sclerosis: a review. QJM Int J Med 111(6):359–364CrossRef McNicholas N et al (2018) Cognitive dysfunction in early multiple sclerosis: a review. QJM Int J Med 111(6):359–364CrossRef
26.
Zurück zum Zitat Gelfand JM et al (2012) Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One 7(5):e36847CrossRef Gelfand JM et al (2012) Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One 7(5):e36847CrossRef
27.
Zurück zum Zitat Oberwahrenbrock T et al (2012) Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int 2012:530305PubMedPubMedCentral Oberwahrenbrock T et al (2012) Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int 2012:530305PubMedPubMedCentral
28.
Zurück zum Zitat Behbehani R et al (2017) Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis. PLoS One 12(2):e0172120CrossRef Behbehani R et al (2017) Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis. PLoS One 12(2):e0172120CrossRef
29.
Zurück zum Zitat Pietroboni AM, Carandini T, Dell’Arti L, Bovis F, Colombi A, De Riz MA, Casazza E, Scola E, Fenoglio C, Arighi A, Fumagalli GG, Triulzi F, Galimberti D, Viola F, Scarpini E (2020) Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurol Sci 41(11):3175–3183. https://doi.org/10.1007/s10072-020-04431-4 Pietroboni AM, Carandini T, Dell’Arti L, Bovis F, Colombi A, De Riz MA, Casazza E, Scola E, Fenoglio C, Arighi A, Fumagalli GG, Triulzi F, Galimberti D, Viola F, Scarpini E (2020) Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurol Sci 41(11):3175–3183. https://​doi.​org/​10.​1007/​s10072-020-04431-4
30.
Zurück zum Zitat Birkeldh U et al (2019) Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis. Mult Scler Relat Disord 36:101414CrossRef Birkeldh U et al (2019) Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis. Mult Scler Relat Disord 36:101414CrossRef
31.
Zurück zum Zitat Klistorner A et al (2014) Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions. Neurology 82(24):2165–2172CrossRef Klistorner A et al (2014) Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions. Neurology 82(24):2165–2172CrossRef
32.
Zurück zum Zitat Yurtoğulları Ş et al (2018) Comparison of Brain Atrophy, Cognition and optical coherence tomography results between multiple sclerosis patients and healthy controls. Noro Psikiyatr Ars 55(1):3–8PubMedPubMedCentral Yurtoğulları Ş et al (2018) Comparison of Brain Atrophy, Cognition and optical coherence tomography results between multiple sclerosis patients and healthy controls. Noro Psikiyatr Ars 55(1):3–8PubMedPubMedCentral
33.
Zurück zum Zitat Rocca MA et al (2015) Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 14(3):302–317CrossRef Rocca MA et al (2015) Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis. Lancet Neurol 14(3):302–317CrossRef
34.
Zurück zum Zitat Damasceno A et al (2015) Subclinical MRI disease activity influences cognitive performance in MS patients. Mult Scler Relat Disord 4(2):137–143CrossRef Damasceno A et al (2015) Subclinical MRI disease activity influences cognitive performance in MS patients. Mult Scler Relat Disord 4(2):137–143CrossRef
35.
Zurück zum Zitat Patti F et al (2009) Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 15(7):779–788CrossRef Patti F et al (2009) Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. Mult Scler 15(7):779–788CrossRef
37.
Zurück zum Zitat Engl C et al (2020) Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy. J Neurol 267(8):2307–2318CrossRef Engl C et al (2020) Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy. J Neurol 267(8):2307–2318CrossRef
38.
Zurück zum Zitat Patti F, De Stefano M, Lavorgna L, Messina S, Chisari CG, Ippolito D, Lanzillo R, Vacchiano V, Realmuto S, Valentino P, Coniglio G, Buccafusca M, Paolicelli D, D’Ambrosio A, Montella P, Brescia Morra V, Savettieri G, Alfano B, Gallo A, Simone I, Viterbo R, Zappia M, Bonavita S, Tedeschi G (2015 ) Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients. PLoS One 10(3):e0120754. https://doi.org/10.1371/journal.pone.0120754 Patti F, De Stefano M, Lavorgna L, Messina S, Chisari CG, Ippolito D, Lanzillo R, Vacchiano V, Realmuto S, Valentino P, Coniglio G, Buccafusca M, Paolicelli D, D’Ambrosio A, Montella P, Brescia Morra V, Savettieri G, Alfano B, Gallo A, Simone I, Viterbo R, Zappia M, Bonavita S, Tedeschi G (2015 ) Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients. PLoS One 10(3):e0120754. https://​doi.​org/​10.​1371/​journal.​pone.​0120754
Metadaten
Titel
Cognitive impairment and markers of optical neurodegeneration in early multiple sclerosis
verfasst von
Renata Silva
Pedro Coelho
Mafalda Seabra
Inês Laranjinha
Daniela Vieira
Octávia Costa
Jennifer Jesus
Ana Cláudia Fonseca
Sónia Costa
Inês Ferreira
João Lemos
Cláudia Sousa
José Vale
Maria José Sá
Luís Ruano
Publikationsdatum
12.02.2022
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 7/2022
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-022-05945-9

Weitere Artikel der Ausgabe 7/2022

Neurological Sciences 7/2022 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.